Intellia Therapeutics price target lowered to $55 from $76 at Barclays
The Fly

Intellia Therapeutics price target lowered to $55 from $76 at Barclays

Barclays lowered the firm’s price target on Intellia Therapeutics (NTLA) to $55 from $76 and keeps an Overweight rating on the shares following the Q3 report.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App